Building Spain's AI Healthcare & Longevity Venture Studio.
A trans-Atlantic platform to originate, build and scale Spain's AI-native Healthcare & Longevity companies into the US market. EBDA Ventures develops proprietary technology in-house, clinically validates with partner institutions, and establishes specialized companies to commercialize each solution.
Originate & build in Spain. Capital & scale in America.
VintageJune 2026
Pharma's $300B revenue cliff has triggered the largest biotech M&A cycle since 2019.
Five of the top-10 pharmas face >50% revenue exposure by 2030. Top-12 pharmas sit on ~$180B of deployable cash. AI-native Healthcare — compressing preclinical discovery from ~4 years to ~13 months — has become the most contested asset class in healthcare.
~20% of industry revenue losing exclusivity by 2030 — 3× the 2016 cliff. ~200 drugs off patent, including ~70 blockbusters.
IQVIA forecasts $140–160B in deal value. $50B+ announced in January 2026 alone. 70% of clinical pipeline sits outside Big Pharma.
Lilly–Insilico (Mar 2026); Lilly–Kelonia $3.25B (Apr 2026); Lilly–Centessa $6.3B. Preclinical → Ph1 is the prized layer.
Source: IQVIA Biopharma M&A (Jan 2026); 2026 = midpoint of forecast range.
AI Healthcare is the only scalable answer to the cliff.
- $350–410B projected annual value AI creates for pharma by 2025
- Preclinical → Phase 1 AI biotechs = most-contested asset layer
- Average upfront $2.5–3.5B per validated AI-designed mechanism
- IPO window still narrow → forced partnerships & exits
Spain has the ingredients. EBDA Ventures builds the platform.
Top-quartile EU scientific talent at 40–60% lower fully-loaded cost than Boston / SF — paired with a built US bridge for capital, customers and clinical access.
STEM PhDs / yr in Spain — ~40% in life sciences or AI-adjacent fields. CNIO, CNIC, BSC, IRB, IDIBAPS, VHIO rank top-quartile in the EU.
Lower fully-loaded scientist cost vs Boston / SF. Senior AI/ML scientist: $115k Madrid vs $285k Boston. 2–3× longer runway per $1M.
Active clinical trials annually across Spain's public system — among the most efficient in the EU. Grifols, Almirall, Rovi, Esteve, PharmaMar anchor commercially.
PERTE Salud, ICO, ENISA, CDTI provide non-dilutive capital alongside private rounds — extending runway and de-risking IND-enabling work.
Co-found with PIs & postdocs from CNIO, BSC, IRB, IDIBAPS, CSIC. The studio platform — clinical, regulatory, finance, AI infra — gets ventures to IND-ready in 12–18 months at 2–3× US capital efficiency.
Series A syndicate and relationship-driven US VC network (Flagship, ARCH, Polaris, OrbiMed, RA, a16z Bio, GV, Founders Fund Bio) + pharma BD (Lilly, Pfizer, Sanofi, Novartis, AZ) + top AMCs (MGB, Dana-Farber, MD Anderson, Mayo, MSK).
Where AI is rewriting the economics of disease.
Women carry a disproportionate share of chronic disease burden across every life stage — a structurally under-funded frontier. AI-native biotechs have raised $13.5B+ over 20 leading platforms; 10 already hold unicorn valuations.
Turner, Rett, congenital heart defects, juvenile arthritis, scoliosis.
Endometriosis, PCOS, eating disorders, infertility, preeclampsia, lupus.
Fibroids, breast cancer, MS, osteoporosis onset, cardiovascular risk rises.
Heart disease (#1 killer), stroke, osteoporotic fractures, breast peak (55–64).
Alzheimer's (women = 2/3 of patients), HFpEF, frailty, hip fractures.
Across the top 20 AI biotech platforms profiled — 2024 to 2026.
Already at $1B+ valuation. Xaira $4B; Altos $5.5B+; Isomorphic $2.5B.
Clinical-stage pipeline now owned by emerging biotechs — most unpartnered.
A studio reaches 10× faster than a VC fund.
By co-founding at €5M pre-money instead of buying into a €25M Series A, EBDA hits a 10× MOIC at a €50M valuation — versus the €500M exit a traditional VC needs for the same multiple. Secondaries deliver partial liquidity at year 5.
Depending on project maturity.
Concentrated build, disciplined pace.
Net of secondaries and follow-ons.
Studio economics + US bridge.
- Entry pre-money
- €5M
- 10× exit at
- €50M valuation
- Liquidity
- Secondary market exits in <5 yrs
- Entry post-money
- €25M (Series A)
- 10× exit at
- €500M valuation
- Liquidity
- Year 8–10 (M&A / IPO)
→ 10× the multiple, at 10% of the exit hurdle. Half the time. Liquidity through secondaries.
EBDA Ventures holds the platform. Every venture is born inside a dedicated SPV.
Each startup launches with a reference Hospital / University / Lab as clinical co-investor (10–30%) validating medical viability before the pre-seed round.
EBDA Ventures
IP · Talent · Capital management
MIRA Health
AI platform · women's longevity
PreventAI
AI cardiometabolic prevention
* Partner hospital stake negotiated 10–30% based on clinical contribution (data, RWE, KOLs, open trial).
The same clinical milestone is worth 12× more in the US.
Pre-Seed and Series A in the US command a 12× premium over Spanish valuations. EBDA leads the process end-to-end: warm intros, US term sheet, governance, materials and due diligence.
Warm intros
Direct access to US partners (Flagship, OrbiMed, Atlas, RA, Perceptive, ARK) via founding team + advisors network.
Story-deck US
Pitch rebuilt in US code: American TAM, comparables, FDA milestones and reimbursement (CHI / PIN / CCM).
Term-sheet US
Negotiation of cap, preferences, anti-dilution, board composition and management terms with US legal counsel.
Long-term commitment
EBDA keeps board seat + pro-rata reserves to follow Series B/C and protect the exit.
- M12–M18
US Newco constitution
- M18–M24
US hospital partner + FDA pre-sub
- M24–M30
Series A close in USD
- M36+
US commercial launch
Structure · pre-seed capital · US scale-up · later-round fundraising · governance and exit. Long-term partner, not broker.
~$38B deployed in biotech venture capital in 2025 — split into two engines.
Venture-creation studios that build companies, and multi-stage / crossover capital that scales them to IPO. EBDA is engineered at their intersection.
The studio model is the premium engine
What leaders do → Flagship founds 8–10 new companies a year; Atlas runs "seed-led venture creation"; RA Capital builds through its Raven incubator. The best returns come from owning origination, not writing checks.
EBDA co-founds AI-healthcare companies inside Spanish research institutions — controlling the company from the first cell line, not bidding for finished deals.
AI-native + proprietary data is the thesis
What leaders do → ARK's ARKG = multiomics × AI × precision medicine, backing platforms that own their data (Recursion, Tempus); Flagship spun up Lila Sciences and Expedition Medicines for AI discovery.
Every EBDA company is AI-native by construction, built around proprietary clinical and biological data from partner institutions — defensible from day one.
Two-pocket capital: lean fund + follow-on
What leaders do → Atlas pairs a $450M creation fund with a $400M Opportunity Fund; OrbiMed and RA layer royalty and structured capital so winners get funded without inflating fund size.
Lean studio fund + per-venture SPVs (2 new SPVs/yr at €150K structuring) to double down on winners while keeping the core fund disciplined.
Source science globally, concentrate the build
What leaders do → Atlas forms companies "around science sourced from around the globe"; OrbiMed runs desks across the US, Europe and Asia. Geography of the science ≠ geography of the capital.
EBDA sources world-class, under-capitalized science in Spain and concentrates company-building where talent is strongest and cost base is lowest.
Build to inflections; a re-opened exit window
What leaders do → Series A rebounded to $50–80M; 65+ biotech IPOs in 2025 raised $12B+ (vs. 22 in 2023); crossover entry is the market's IPO-readiness signal.
EBDA builds to crisp seed / Series A inflections, then brings in US crossover capital for scale-up and exit — IPO or strategic M&A.
US private healthcare markets price assets at a 3–5× premium to Europe.
Same science. Same stage. Different zip code. The transatlantic valuation gap is the most attractive arbitrage in life-sciences VC today — and it is widening, not closing.
3.4× more capital deployed in US healthcare VC than in Europe in 2025.
PitchBook 2024 — same stage, different market.
EBDA Ventures is the team — and the network it commands.
Direct access to top US life-sciences funds, the FDA, leading AMCs, and the world's most decorated longevity & genomics scientists.
Emilio Escartín
Managing Founder
30+ yrs VC / PE + global direct investments.
CUNEF · IESE · IE · Harvard Univ.
- Manuel Collado, PhDPresident, The Lab of Cell Senescence · Global leader, Cancer & Aging
- María Blasco, PhDDirector & Head, CNIO · Global leader, Cancer & Aging (Telomeres)
- George Church, PhDProfessor, Harvard Medical School & MIT · Founder of modern genomics
- Peter H. Diamandis, MDFounder, X Prize · CEO, Singularity University
- David Sinclair, AO, PhDProfessor, Harvard Medical School · The Sinclair Lab
- Brian Kennedy, MD, PhDProfessor, NUS Yong Loo Lin · former Buck Institute CEO
Healthcare VCs
Flagship, ARCH, Polaris, OrbiMed, F-Prime, Third Rock, Atlas, RA Capital, a16z Bio, GV, Founders Fund Bio, Lux, Khosla
Pharma BD & Strategic
Lilly, Pfizer, Sanofi, Novartis, AstraZeneca, Roche/Genentech · NVIDIA Inception · AWS for Life Sciences
Top US AMCs & Hospitals
Mass General Brigham, Dana-Farber, MD Anderson, Mayo Clinic, MSK, Cleveland Clinic, Cedars-Sinai, Houston Methodist
Regulatory & Clinical
FDA pre-IND advisory pipeline · top-tier US CROs / CDMOs · EMA dialogue alongside FDA
KOLs & Academia
Harvard, MIT, Stanford, UCSF, Columbia, UCSD, Berkeley · CNIO, CSIC, BSC, IRB, VHIO, IDIBAPS